Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of BGF 160 on Ventilation Patterns in Stable COPD
NCT06110403Phase 2Recruiting
- Sponsor
- CHU de Lille
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EPI-EE, glycopyrrolate metered dose inhaler, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by CHU de Lille. Started Sep 2023; status: recruiting.
02
Drugs
EPI-EEglycopyrrolate metered dose inhalerformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06110403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110403.